A study led by CeMM-AITHYRA in Vienna, with contributions from the Institute for Research in Biomedicine of Barcelona (IRB Barcelona), based in the Barcelona Science Park, reveals that kinase inhibitors not only block enzymatic activity but can also accelerate the degradation of target proteins, uncovering a pharmacological mechanism that is widespread yet previously overlooked. The findings, published in Nature, show that drug-induced degradation is not a rarity, but a common and potentially exploitable feature of kinase inhibitor pharmacology.

For decades, kinase inhibitors have been a mainstay of cancer therapy, designed to switch off enzymes that fuel uncontrolled cell growth. But new research shows that these drugs often go further: they can also cause the very proteins they target to be dismantled by the cell, making them yet another tool for the emerging field of Targeted Protein Degradation (TPD).

Protein kinases are the molecular switches of the cell. They control growth, division, communication, and survival by attaching phosphate groups to other proteins. When these switches are stuck in the “on” position, they can drive cancer and other diseases. Not surprisingly, kinases have become one of the most important drug target families in modern medicine: today, more than 80 kinase inhibitors are FDA-approved, and nearly twice as many are in clinical development.

These drugs were designed to block enzymatic activity. But a new study led by CeMM, the Research Center for Molecular Medicine of the Austrian Academy of Sciences (Vienna), the AITHYRA Institute for Artificial Intelligence in Biomedicine (Vienna), and the Institute for Research in Biomedicine (Barcelona), together with partners across Europe, the US and China, reveals a surprising twist: kinase inhibitors can also accelerate the degradation of the very proteins they target. The findings, published in Nature, show that drug-induced degradation is not a rare quirk but a common and potentially exploitable feature of kinase inhibitor pharmacology.

As part of the international consortium, IRB Barcelona scientists played a key role in shaping the analytical framework behind these findings. Dr. Patrick Aloy, Dr. Martino Bertoni and Dr. Arnau Comajuncosa-Creus developed the drug-screen scoring strategy and supervised the associated data analysis, which enabled the systematic identification of degradation events across the inhibitor library.

“These results redefine how we think about kinase inhibitors. Recognising protein degradation as part of their mechanism expands the possibilities for designing therapies that eliminate disease-driving proteins more effectively,” says Dr. Patrick Aloy, ICREA Research Professor and head of the Structural Bioinformatics and Network Biology at IRB Barcelona.

A systematic look at an overlooked phenomenon

Hints that inhibitors might destabilize their targets had surfaced before, but the scope and mechanisms were unclear. To address this, the researchers systematically profiled 98 kinases with a library of 1,570 Inhibitors, monitoring protein abundance over time. The result was striking: 232 compounds lowered the levels of at least one kinase, with 66 different kinases affected.

Some of these cases followed the known route of the so-called “chaperone deprivation”, where inhibitor binding prevents the stabilizing chaperone HSP90 from protecting its client kinases. But many others did not. Instead, the team discovered a shared mechanistic principle: inhibitors can push kinases into altered states through changes in activity, localization, or assembly, which are naturally unstable and therefore cleared more quickly by the cell’s own proteolytic circuits.

“Inhibitor-induced degradation turns out to be surprisingly widespread,” says Dr. Natalie Scholes, senior postdoctoral researcher at CeMM and first author of the study. “Our data show that small molecules don’t just block kinase activity; they can shift proteins into conformations that the cell recognises as unstable. That means inhibitors can double as degraders, adding a whole new layer to how these drugs work.”

Three case studies, one unifying principle

To dissect these mechanisms, the researchers focused on three kinases with very different fates: The researchers illustrated this principle with three examples: one kinase (LYN) was eliminated within minutes once an inhibitor tipped its natural stability switch; another (BLK) was broken down only after being released from the cell membrane into the cytosol by a membrane-bound protease complex; and a third (RIPK2) was cleared after forming large protein clusters that the cell recognized and removed through its recycling machinery. Together, these cases illustrate a broader rule: inhibitors can “supercharge” endogenous degradation pathways, nudging kinases into unstable states that the cell’s quality-control machinery removes.

“This study demonstrates that degradation is not an anomaly but part of the pharmacological spectrum of kinase inhibitors,” says Dr. Georg Winter, Director at the AITHYRA Institute for Biomedical AI, adjunct Principal Investigator at CeMM and senior author of the study. “Understanding this dimension could help us design better drugs that don’t just silence kinases but remove them altogether—and in some cases, it may explain unexpected effects of existing therapies.”

» Article of reference: Inhibitors supercharge kinase turnover through native proteolytic circuits. Natalie S. Scholes, Martino Bertoni, Arnau Comajuncosa-Creus, Katharina Kladnik, Xuefei Guo, Fabian Frommelt, Matthias Hinterndorfer, Hlib Razumkov, Polina Prokofeva, Martin P. Schwalm, Florian Born, Sandra Roehm, Hana Imrichova, Brianda L. Santini, Eleonora Barone, Caroline Schätz, Miquel Muñoz i Ordoño, Severin Lechner, Andrea Rukavina, Iciar Serrano, Miriam Abele, Anna Koren, Stefan Kubicek, Stefan Knapp, Nathanael S. Gray, Giulio Superti-Furga, Bernhard Kuster, Yigong Shi, Patrick Aloy, Georg E. Winter. Nature (2025) DOI: 10.1038/s41586-025-09763-9

» Link to the news: IRB Barcelona website [+]